| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
6 companies
Fairbairn Robert W is a Director at ECAT, with reported holdings spanning 6 companies. Recent filings cover 11 purchases and 48 sales. Those positions are worth an estimated $1.4M at current prices.
Our model assigns Fairbairn Robert W a middling insider score of 63/100, based on 12 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +2.0%.
Fairbairn Robert W's largest disclosed position is in ECAT as Director, worth about $781K. Net of sales, the recent Form 4 record there shows accumulation of 53,880 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2020 | BSTZ Blackrock Science & Technology Term Trust | Director | Buy | 6,835 | $36.33 | $248,332.64 | New | |
| Dec 21, 2020 | BCAT Blackrock Capital Allocation Term Trust | Director | Buy | 43,141 | $22.97 | $991,121.35 | +287.6% | |
| Sep 24, 2020 | BCAT Blackrock Capital Allocation Term Trust | Director | Buy | 15,000 | $20.00 | $300,000.00 | New | |
| Jan 28, 2020 | BMEZ Blackrock Health Sciences Term Trust | Director | Buy | 15,000 | $20.00 | $300,000.00 | New |